DoD JPC8/CRMRP Regenerative Medicine Focused Research Award (AFIRM III) | W81XWH 19 DMRDP RMFRA

Opportunity Information: Apply for W81XWH 19 DMRDP RMFRA

The DoD JPC-8/CRMRP Regenerative Medicine Focused Research Award (AFIRM III) is a Department of Defense research funding opportunity designed to speed up practical regenerative medicine solutions for injuries related to trauma, with particular attention to repairing, reconstructing, or regenerating tissues that have been lost or badly damaged. The program is structured around the idea that meaningful progress in this space usually does not come from isolated projects, but from coordinated efforts where teams and partner organizations align their work so that individual studies reinforce one another. In other words, the award is meant to support collaborative partnerships and tightly connected, synergistic projects that can collectively move the field forward faster than standalone research.

A central theme of this opportunity is translation: the funded research is expected to push the most promising solutions and enabling technical capabilities toward advanced development and eventual real-world use. The announcement makes it clear that outputs should be more than academic insights. The products of the research, described as material or knowledge products, should be positioned for transition into medical practice and/or commercialization. That means applicants are expected to think early about how a therapy, device, biomaterial, biologic strategy, or other regenerative approach could realistically be adopted by clinicians as a surgical or therapeutic option, or otherwise be developed into something that can reach patients through commercial pathways. The emphasis on transition implies a preference for work that reduces key scientific, technical, manufacturing, regulatory, or clinical barriers that typically prevent regenerative technologies from moving beyond the lab.

The opportunity also reflects the complexity of regenerating peripheral nerve and skeletal muscle, where successful outcomes often require multiple complementary strategies rather than a single intervention. The program anticipates that the best approaches will be multifaceted and will span both Focus Areas and multiple Areas of Encouragement (as defined in the full program materials). Practically speaking, this suggests projects may need to integrate several lines of work, such as combining biomaterials with cells or biologics, pairing rehabilitation or stimulation strategies with tissue engineering, developing new models or measurement methods that make results more predictive for clinical translation, or building toolkits and platforms that can be reused and scaled. The expectation of multifaceted solutions signals that proposals which connect different technical components into a coherent, end-to-end development plan are likely to align well with the intent of the award.

From an administrative standpoint, the funding is offered by the Department of Defense, Department of the Army, through USAMRAA, under CFDA 12.420. The opportunity is listed as discretionary and supports awards via cooperative agreements and grants, which typically indicates that, depending on the mechanism used for a specific award, the government may have substantial involvement in program coordination, milestones, or collaboration expectations. Eligibility is described as unrestricted, meaning it is broadly open to a wide range of applicant organization types, subject to any additional eligibility clarifications in the full notice. The original posting dates show a creation date of June 19, 2019, with an original closing date of November 20, 2019, and the program anticipated making about five awards. The listing shows an award ceiling of 0, which commonly indicates the ceiling was not specified in the summary record and would need to be confirmed in the detailed funding announcement.

Overall, this award mechanism is aimed at research teams that can demonstrate both strong science and a credible path to impact, including a clear plan for how the proposed regenerative medicine solution or enabling capability will be matured, validated, and prepared for transition. It is not simply a call for early discovery; it is a call for focused, coordinated development work that produces tangible outputs with a realistic chance of becoming usable medical options for traumatic injury care.

• The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD JPC8/CRMRP Regenerative Medicine Focused Research Award (AFIRM III)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
• This funding opportunity was created on Jun 19, 2019.
• Applicants must submit their applications by Nov 20, 2019. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• The number of recipients for this funding is limited to 5 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for W81XWH 19 DMRDP RMFRA

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: